An Open Label, Multi-centre Trial of Alipogene Tiparvovec for the Treatment of LPLD Patients
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 27 Jul 2017
At a glance
- Drugs Alipogene tiparvovec (Primary) ; Ciclosporin; Mycophenolate mofetil; Prednisolone
- Indications Hyperlipoproteinaemia type I
- Focus Therapeutic Use
- Sponsors uniQure
- 20 Jul 2017 Status changed from recruiting to withdrawn prior to enrolment because uniQure., has decided not to renew the Marketing Authorization of Glybera in the EU and this decision is not related to any safety, efficacy or quality issue .
- 13 Oct 2016 Status changed from not yet recruiting to recruiting.
- 03 Oct 2016 Planned initiation date changed from 1 Sep 2016 to 1 Oct 2016.